KYTX Share Price Performance
US$8.01
4.77 (147.22%)
77.1% undervalued intrinsic discount
US$35.00
Fair Value
Price US$8.01
yygchong US$35.00
Fair ValueUS$35.00
Share Pricen/a
Kyverna Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
KYTX Community Narratives
YY
Fair Value US$35 77.1% undervalued intrinsic discount
Kyverna Bull Case
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Kyverna Bull Case
Kyverna has the most experienced and proven leadership team to bring CAR-T products to market (Former Kite exectuvies running the top positons and holding board positions) of whom have experience in this new field in scaling manufacturing and marketing these products. Kyverna also has an ample funding beyond most of its peers with a runway well into 3 years without additional fundraising or milestone payments.Read more
40
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
YY
US$35
77.1% undervalued intrinsic discount
yygchong's Fair Value
Profit Margin
19.56%
Future PE
N/A
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
YY
Kyverna Bull Case
Fair Value: US$35 77.1% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Kyverna Therapeutics, Inc. Key Details
About KYTX
- Founded
- 2018
- Employees
- 129
- CEO
- WebsiteView website
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
